- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05849064
Concussion Treatment in Older Adults
September 7, 2023 updated by: Anthony P. Kontos, Ph.D., University of Pittsburgh
Randomized Controlled Trial of Targeted Treatment in Older Adults Following Concussion
The purpose of this study is to conduct the first randomized control trial for targeted treatments for concussion in adults 50 years or older.
Participants will be enrolled at their first concussion clinical visit (V1) and their second study visit will occur after (up to 7 days) or concurrently with the participant's second concussion clinical visit, typically (but not limited to) between 21-31 days from V1.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Although concussion is a common occurrence in older adults, we know little about the injury in this at-risk population.
Certain management tools that might be appropriate for adolescent and young adult populations may not be appropriate for use in older adults who may have sensory, cognitive, and neuro-motor limitations.
This study will help to develop initial evidence for targeted treatments for concussion in older adults.
The study will utilize a two group design with permuted block random assignment to intervention and usual care/control groups.
All participants will complete the following assessments at their initial and follow-up visit appointments: cognitive screening (learning, memory, language, executive functioning), concussion and mood symptom questionnaires, and neuro-motor screening.
The primary outcomes for this study will be total symptom severity score (i.e., symptom burden) on the Concussion Clinical Profiles Screening (CP Screen) and Patient Global Impression of Change (PGIC).
Secondary outcomes will include: Short Falls Efficacy Scale (SFES), Dizziness Handicap Inventory (DHI), Patient Health Questionnaire-9 (PHQ-9), Patient Health Questionnaire-15 (PHQ-15), Generalized Anxiety Disorder - 7 (GAD-7), Posttraumatic Stress Disorder Checklist (PCL-5), Pittsburgh Sleep Quality Index (PSQI), Neuro-Quality of Life (QOL) v2.0 - Cognition Function (Short version), Headache Impact Test (HIT-6), ID Migraine, Neck Disability Index (NDI), Vestibular Ocular Motor Screen (VOMS), Timed-Up-and-Go (TUG), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
All outcomes will be treated as continuous.
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anthony Kontos, PhD
- Phone Number: 412-432-3725
- Email: akontos@pitt.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15203
- Recruiting
- University of Pittsburgh
-
Contact:
- Anthony P Kontos, PhD
- Phone Number: 412-432-3725
- Email: akontos@pitt.edu
-
Principal Investigator:
- Anthony P Kontos, PhD
-
Contact:
- Courtney Perry, MS
- Phone Number: 412-904-1298
- Email: cap236@pitt.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 50 years of age or older
- Diagnosed concussion within the last 4 days - 12 months
- Must be recruited at their initial concussion appointment
- Ability to read/write to complete study assessments/testing
Exclusion Criteria:
- Diagnosed neurological disorder (stroke, dementia, epilepsy)
- Diagnosed major psychiatric disorders other than depression/anxiety (e.g., schizophrenia)
- Diagnosed with moderate to severe brain injury or past brain surgery/malformations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Behavioral Control
Participants randomized to the behavioral control group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
|
Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies.
These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
|
Experimental: Targeted Intervention
Participant receives exercises or strategies based on their clinical concussion domain given to them by their neuropsychologist: 1) Anxiety/Mood, 2)Headache/Migraine, 3)Vestibular, 4)Ocular, 5)Cognitive.
|
Participants will be prescribed one or more interventions, tailored to their domains.
Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors.
Graded exposure/activity/relaxation exercises, cognitive restructuring.
Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities.
Migraine/Headache: Education, relaxation training/mindfulness based therapy.
Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits.
Sleep-Sleep regulation/hygiene.
Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concussion Clinical Profiles Screening (CP Screen)
Time Frame: Visit 1 (Baseline)
|
The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical.
Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item.
The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87.
|
Visit 1 (Baseline)
|
Concussion Clinical Profiles Screening (CP Screen)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The CP Screen is a 29 item self-report, clinical profiles based symptom inventory that measures five concussion clinical profiles: 1) anxiety/mood, 2)cognitive/fatigue, 3) migraine, 4) ocular, 5) vestibular; and two modifying factors sleep and cervical.
Participants indicate on a scale of 0 (none) to 3 (severe) the level of symptom severity for each item.
The CP screen yields an average factor and modifier scores, with higher scores indicative of worse symptom severity, score range is 0-87.
|
At study completion, an average of 30 days after Visit 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vestibular/Ocular Motor Screening (VOMS)
Time Frame: Visit 1 (Baseline)
|
The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS).
Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms.
Symptoms in each area are rated on scale 0 (none) to 10 (severe).
Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment.
|
Visit 1 (Baseline)
|
Vestibular/Ocular Motor Screening (VOMS)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The VOMS assesses impairment via patient report symptom provocation following each of 5 test components (smooth pursuits, horizontal/vertical saccades, convergence, horizontal and vertical vestibular ocular reflex (VOR) and visual motor sensitivity (VMS).
Patients verbally rate changes in headache, dizziness, nausea, and fogginess after each test, as well as report their baseline symptoms.
Symptoms in each area are rated on scale 0 (none) to 10 (severe).
Scores on any VOMS item of 2+ reflects a positive screening cut-off for vestibular and/or ocular motor impairment.
|
At study completion, an average of 30 days after Visit 1
|
Short Falls Efficacy Scale (SFES)
Time Frame: Visit 1 (Baseline)
|
The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities.
Question responses are scaled from 1-4, with higher scores indicating more concern for falls.
(Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28).
|
Visit 1 (Baseline)
|
Short Falls Efficacy Scale (SFES)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The SFES is a 7 item survey that measures a subject's fear and concerns about falling during normal daily life activities.
Question responses are scaled from 1-4, with higher scores indicating more concern for falls.
(Low concern = 7-8; Moderate concern = 9-13; High concern = 14-28).
|
At study completion, an average of 30 days after Visit 1
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Visit 1 (Baseline)
|
The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression.
Total score ranges from 1-27, with higher scores indicating higher level of depression.
Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day).
|
Visit 1 (Baseline)
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression.
The PHQ-9 is a 9 item questionnaire that assesses the presence and severity of depression.
Total score ranges from 1-27, with higher scores indicating higher level of depression.
Scale is 0-4 (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day).
|
At study completion, an average of 30 days after Visit 1
|
Patient Health Questionnaire-15 (PHQ-15)
Time Frame: Visit 1 (Baseline)
|
The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot").
Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30).
|
Visit 1 (Baseline)
|
Patient Health Questionnaire-15 (PHQ-15)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The PHQ-15 comprises 15 somatic symptoms that are scored from 0 ("not bothered at all") to 2 ("bothered a lot").
Higher scores are indicative of higher levels of depression (Minimal =0-4; Low = 5-9; Medium = 10-14; High = 15=30).
|
At study completion, an average of 30 days after Visit 1
|
General Anxiety Disorder-7 (GAD-7)
Time Frame: Visit 1 (Baseline)
|
The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety.
Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day.
Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety.
|
Visit 1 (Baseline)
|
General Anxiety Disorder-7 (GAD-7)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The GAD-7 is a seven item self-reported questionnaire that measures severity of symptoms regarding anxiety.
Responses are 0 = not at all, 1 = several days, 2= more than half the days, and 3 = nearly every day.
Higher scores are indicative of higher anxiety (0-4 = minimal anxiety, 5-9= mild anxiety, 10-14 =moderate anxiety, 15-21 = severe anxiety.
|
At study completion, an average of 30 days after Visit 1
|
PCL-5
Time Frame: Visit 1 (Baseline)
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely).
Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80)
|
Visit 1 (Baseline)
|
PCL-5
Time Frame: At study completion, an average of 30 days after Visit 1
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
Responses are on a 5 point likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely).
Overall score is total sum of 20 items with higher scores indicating higher level of PTSD (Range 0-80).
|
At study completion, an average of 30 days after Visit 1
|
Neuro-QOL (Cognitive Function Scale - short form)
Time Frame: Visit 1 (Baseline)
|
The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning).
The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day.
Total scores range from 0-40.
Higher scores indicate better self-reported cognitive function.
|
Visit 1 (Baseline)
|
Neuro-QOL (Cognitive Function Scale - short form)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The cognitive function measures perceived difficulties in cognitive abilities (e.g., memory, attention, and decision making, or in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering and learning).
The short form contains 8 items, scored 0-5 (5=never, 4=rarely/once, 3=sometimes/2-3 times, 2=often/once a day, 1=very often/several times per day.
Total scores range from 0-40.
Higher scores indicate better self-reported cognitive function.
|
At study completion, an average of 30 days after Visit 1
|
Dizziness Handicap Inventory (DHI)
Time Frame: Visit 1 (Baseline)
|
The DHI is a 25 item self-reported measure that examines dizziness-related handicap.
The assessment has 3 domains (functional, emotional, and physical).
Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed.
There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional).
Minimum score is 0.
|
Visit 1 (Baseline)
|
Dizziness Handicap Inventory (DHI)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The DHI is a 25 item self-reported measure that examines dizziness-related handicap.
The assessment has 3 domains (functional, emotional, and physical).
Participants self-report the level dizziness has impacted their abilities in the 3 domains with each domain having 9 questions (questions are answered No (0)/Sometimes(2)/Yes(4)) Item scores are summed.
There is a maximum score of 100 (28 points for physical, 36 points for emotional and 36 points for functional).
Minimum score is 0.
|
At study completion, an average of 30 days after Visit 1
|
Headache Impact Test-6 (HIT-6)
Time Frame: Visit 1 (Baseline)
|
The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches.
Items score from 6 to 13, with higher scores indicating worse severity.
Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points.
Score range 36-78.
|
Visit 1 (Baseline)
|
Headache Impact Test-6 (HIT-6)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The HIT-6 is comprised of 6 self-report items that assess frequency, severity and limitations of daily activities, fatigue, irritability, and concentration related to headaches.
Items score from 6 to 13, with higher scores indicating worse severity.
Scores = never = 6pts, rarely = 8 pts, sometimes = 10pts, very often = 11 pts, always = 13 points.
Score range 36-78.
|
At study completion, an average of 30 days after Visit 1
|
ID Migraine
Time Frame: Visit 1 (Baseline)
|
The ID Migraine will be used to screen for headache symptoms.
It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain.
Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines.
|
Visit 1 (Baseline)
|
ID Migraine
Time Frame: At study completion, an average of 30 days after Visit 1
|
The ID Migraine will be used to screen for headache symptoms.
It is a 3 item screening tool designed to assess presence (yes/no) of symptoms related to headache/migraine pain.
Scores range from 0-3 with clinical cut-off of 2+ indicating presence of migraines.
|
At study completion, an average of 30 days after Visit 1
|
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: Visit 1 (Baseline)
|
RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory.
There are total scores and indices scores, which are different depending on age and gender.
Higher scores indicate better performance for all 5 domains.
(<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior).
|
Visit 1 (Baseline)
|
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: At study completion, an average of 30 days after Visit 1
|
RBANS provides a brief, individually administered battery to measure cognitive decline or improvement across 5 domains (Immediate memory, visuospatial/constructional, language, attention, and delayed memory.
There are total scores and indices scores, which are different depending on age and gender.
Higher scores indicate better performance for all 5 domains.
(<69=extremely low, 70-79=borderline, 80-89-low average, 90-109=average, 110-119=high average, 120-129=superior, 130 and higher = very superior).
|
At study completion, an average of 30 days after Visit 1
|
Neck Disability Index
Time Frame: Visit 1 (Baseline)
|
Neck pain scale, each item scores 0-5 with range 0-50.
Overall score out of 50 is multiplied by 100 to get a percentage.
0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms.
|
Visit 1 (Baseline)
|
Neck Disability Index
Time Frame: At study completion, an average of 30 days after Visit 1
|
Neck pain scale, each item scores 0-5 with range 0-50.
Overall score out of 50 is multiplied by 100 to get a percentage.
0-20% = minimal disability, 20-40% is moderate disability, 40-60% severe disability, 60-80% = crippled, 80-100% =participants are either bed-bound or exaggerating symptoms.
|
At study completion, an average of 30 days after Visit 1
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Visit 1 (Baseline)
|
The PSQI assesses sleep quality.
It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction.
Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad).
Higher scores indicate more sleep dysfunction.
Score range is 0-21.
|
Visit 1 (Baseline)
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: At study completion, an average of 30 days after Visit 1
|
The PSQI assesses sleep quality.
It is an 19 item self-reported measure that is comprised of seven component scores: 1) subjective sleep quality, 2) sleep latency, 3) sleep duration, 4) sleep efficiency, 5) sleep disturbances, 6) sleep medication usage, and 7) daytime dysfunction.
Each item is scored 0-3 (0 = very good, 1 = fairly good, 2= fairly bad, 3=very bad).
Higher scores indicate more sleep dysfunction.
Score range is 0-21.
|
At study completion, an average of 30 days after Visit 1
|
Timed-Up-and-Go
Time Frame: Visit 1 (Baseline)
|
Walking balance test, distance of 3 meters (10 feet).
Participants are timed.
Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down.
Participants will repeat this 3 times, and we will use the average time.
< 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid.
Higher scores indicating more problems with mobility.
|
Visit 1 (Baseline)
|
Timed-Up-and-Go
Time Frame: At study completion, an average of 30 days after Visit 1
|
Walking balance test, distance of 3 meters (10 feet).
Participants are timed.
Participants are seated in a chair, instructed to get up, walk 3 meters (marked on floor or by cone), round the cone, return to the chair and sit back down.
Participants will repeat this 3 times, and we will use the average time.
< 10 second = normal, <20 seconds, good mobility, <30 second, problems/may require aid.
Higher scores indicating more problems with mobility.
|
At study completion, an average of 30 days after Visit 1
|
Patient's Global Impression of Change (PGIC)
Time Frame: Daily between Visit 1 and study completion, an average of 30 days
|
PGIC is a self-reported assessment of change.
Participants rate their impression of how much better they feel on a 7 point likert scale.
It is a 1 item survey, with higher scores representing no change and associated with feeling worse.
(Responses 1=much improved, 2=minimally improved, 3=no change, 4=minimally worse, 5=much worse, 6=very much worse).
|
Daily between Visit 1 and study completion, an average of 30 days
|
Percent Back to Normal
Time Frame: Daily between Visit 1 and study completion, an average of 30 days
|
Subject rates on a scale from 0% to 100% how much they feel like they are back to normal (before injury)
|
Daily between Visit 1 and study completion, an average of 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anthony Kontos, PhD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 7, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 13, 2023
First Submitted That Met QC Criteria
May 4, 2023
First Posted (Actual)
May 8, 2023
Study Record Updates
Last Update Posted (Actual)
September 8, 2023
Last Update Submitted That Met QC Criteria
September 7, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY23020055
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Concussion, Mild
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingMild Traumatic Brain Injury | Concussion, Mild | Concussion, Severe | Concussion, IntermediateUnited States
-
Sync-Think, Inc.CompletedBrain Injuries | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion; Eye | Concussion, CerebralUnited States
-
BrainScope Company, Inc.CompletedBrain Injuries, Traumatic | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, IntermediateUnited States
-
BrainScope Company, Inc.CompletedBrain Injuries, Traumatic | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, IntermediateUnited States
-
BrainScope Company, Inc.United States Department of DefenseCompletedBrain Injuries, Traumatic | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, IntermediateUnited States
-
BrainScope Company, Inc.CompletedBrain Injuries, Traumatic | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, IntermediateUnited States
-
BrainScope Company, Inc.United States Department of DefenseCompletedBrain Injuries, Traumatic | Concussion, Mild | Concussion, Brain | Concussion, Severe | Concussion, IntermediateUnited States
-
Medstar Health Research InstituteNot yet recruitingConcussion, Mild | Concussion, Severe | Concussion, Intermediate
-
Sports Surgery Clinic, Santry, DublinUnknownConcussion, Mild | Concussion, Severe | Concussion, IntermediateIreland
-
University of British ColumbiaUnknownConcussion | Sport-related Concussion | Mild Traumatic Brain Injury (MTBI)Canada
Clinical Trials on Behavioral Control
-
Atlanta VA Medical CenterCompletedUrinary Incontinence | NocturiaUnited States
-
Penn State UniversityCompletedGene Expression in Response to Acute StressUnited States
-
The Miriam HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
The University of Texas Health Science Center at...CompletedSecondary Prevention | Public Health | Sexually Transmitted Disease | Behavioral ModificationUnited States
-
Northeastern UniversityNational Institute on Aging (NIA)Completed
-
University Hospital Inselspital, BerneUniversity of Zurich; Swiss National Science Foundation; University of BernTerminatedMyocardial Infarction | Stress Disorders, Post-TraumaticSwitzerland
-
Mayo ClinicCompletedSmoking CessationUnited States
-
University of Wisconsin, MadisonNational Institute of Nursing Research (NINR)CompletedPain | Cancer | Fatigue | Sleep DisturbanceUnited States
-
Ege UniversityCompleted
-
University of ArizonaNational Center for Complementary and Integrative Health (NCCIH)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Cigarette | Smoking Habit | Smoking (Tobacco) AddictionUnited States